Press "Enter" to skip to content

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint – UroToday

admin 0

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint  UroToday

Bone metastases in patients with metastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), cabozantinib versus …

“prostate cancer” – Google News

(Visited 5 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *